LogicBio, launched in 2016, is building on the pioneering work of gene therapy leaders from Stanford University.
Our technology, GeneRide™, enables highly specific genome editing and integration of the therapeutic transgene, utilizing the body's own native processes to drive durable expression.
We are initially targeting a wide range of diseases not addressable today, including early-onset conditions in young patients.
We are a world-class global team, headquartered in Cambridge, Massachusetts, working to deliver the next wave of innovation in genetic medicine.
President and Chief Executive Officer
Frederic Chereau has more than 25 years of experience leading groundbreaking biotherapeutics companies, and successfully guiding products from proof-of-concept and clinical trial through commercialization. Prior to joining LogicBio, Fred held various general management and biotech executive positions at Genzyme, Pervasis Therapeutics, Shire and aTyr Pharma. He holds an undergraduate degree in physics from Paris University, a Master’s degree from ESC La Rochelle and an MBA from INSEAD.
Chief Financial Officer
Matthias Jaffé is an accomplished leader in early life science financial and strategic management. Over the last 15 years, Matthias has served as chief financial officer for Constellation Pharmaceuticals, Zafgen, Pervasis Therapeutics and Alantos Pharmaceuticals. He holds an M.Sc. from MIT and an MBA from INSEAD, and is an avid paragliding pilot.
Chief Business Officer
Tom Wilton has an extensive background in business development, corporate strategy and commercial operations across the pharma, academic and biotech sectors. Previously, Tom served as chief business officer for the University of Pennsylvania’s Gene Therapy Program, and played an instrumental role in the establishment of GSK’s Rare Diseases Business Unit. He holds graduate degrees from the University of Leeds and Brunel University.
Nelson Chau, Ph.D.
Vice President, Discovery Biology and Translational Research
Nelson Chau is a seasoned biotech veteran with deep experience in drug discovery and translational research. Prior to joining LogicBio, he served as vice president of drug discovery at Translate Bio and director of research at Regulus Therapeutics where he contributed to the discovery and preclinical development of multiple RNA-based therapeutics. Nelson earned his Ph.D. from the Johns Hopkins University School of Medicine and was a Damon Runyon Fellow.
Clinical and Regulatory Strategist
A specialist in rare disease and deep clinical drug development, Kelly Blackburn has built a career guiding transformative drugs from first-in-human trials to launch. She began her career at Bayer and Genetics Institute, and later went on to drive clinical development programs at Millennium Pharmaceuticals, Vertex and aTyr Pharma. Kelly holds a B.S. in biochemistry from the University of New Hampshire, an M.H.A. from Quinnipiac University and an M.Ed. from Cambridge College. Away from the office, Kelly devotes herself to non-profit work.
Kyle Chiang, Ph.D.
Vice President, Portfolio Management and Operations
Kyle Chiang has more than 10 years of rare disease drug development experience as a key member of discovery and clinical science teams. Most recently, he served as program executive of ATYR1940 at aTyr Pharma, where he led the program through early clinical development for patients with facioscapulohumeral muscular dystrophy. Kyle received his Ph.D. in macromolecular cellular structure and chemistry from the Scripps Research Institute.